{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T23:04:36Z","timestamp":1789167876864,"version":"build-2803163510"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,10]],"date-time":"2020-12-10T00:00:00Z","timestamp":1607558400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","award":["INT18\/13"],"award-info":[{"award-number":["INT18\/13"]}],"id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"Associazione Italiana per la Ricerca sul Cancro","doi-asserted-by":"publisher","award":["IG 18386"],"award-info":[{"award-number":["IG 18386"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.esmoop.2020.100034","type":"journal-article","created":{"date-parts":[[2021,1,10]],"date-time":"2021-01-10T00:37:19Z","timestamp":1610239039000},"page":"100034","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Single-arm, open label prospective trial to assess prediction of the role of\u00a0ERCC1\/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy"],"prefix":"10.1016","volume":"6","author":[{"given":"M.","family":"Ganzinelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Linardou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.F.","family":"Alvisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Caiola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Lo Russo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.L.","family":"Cecere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.C.","family":"Bettini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Psyrri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Milella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Rulli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"De Maglie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Romanelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Broggini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Marabese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.C.","family":"Garassino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2020.100034_bib1","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.ctrv.2019.03.004","article-title":"Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out","volume":"75","author":"Proto","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2020.100034_bib2","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2020.100034_bib3","doi-asserted-by":"crossref","first-page":"148","DOI":"10.2478\/raon-2019-0018","article-title":"Cisplatin and beyond: molecular mechanisms of action and drug resistance development in cancer chemotherapy","volume":"53","author":"Makovec","year":"2019","journal-title":"Radiol Oncol"},{"key":"10.1016\/j.esmoop.2020.100034_bib4","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1021\/cr068207j","article-title":"Direct cellular responses to platinum-induced DNA damage","volume":"107","author":"Jung","year":"2007","journal-title":"Chem Rev"},{"key":"10.1016\/j.esmoop.2020.100034_bib5","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","article-title":"The resurgence of platinum-based cancer chemotherapy","volume":"7","author":"Kelland","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib6","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/(SICI)1097-0215(19960611)66:6<779::AID-IJC12>3.0.CO;2-Z","article-title":"Sensitivity of CHO mutant cell lines with specific defects in nucleotide excision repair to different anti-cancer agents","volume":"66","author":"Damia","year":"1996","journal-title":"Int J Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib7","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.dnarep.2015.09.003","article-title":"Nucleotide excision repair in humans","volume":"36","author":"Spivak","year":"2015","journal-title":"DNA Repair (Amst)"},{"key":"10.1016\/j.esmoop.2020.100034_bib8","doi-asserted-by":"crossref","first-page":"6933","DOI":"10.1007\/s11033-012-1520-4","article-title":"ERCC1 expression as a prognostic and predictive factor in patients with non-small cell lung cancer: a meta-analysis","volume":"39","author":"Jiang","year":"2012","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.esmoop.2020.100034_bib9","doi-asserted-by":"crossref","first-page":"2245","DOI":"10.1007\/s00432-017-2516-1","article-title":"Methodological quality evaluation of systematic reviews or meta-analyses on ERCC1 in non-small cell lung cancer: a systematic review","volume":"143","author":"Tao","year":"2017","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100034_bib10","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1200\/JCO.2016.70.5053","article-title":"ERCC1 as predictor of platinum benefit in non-small-cell lung cancer","volume":"35","author":"Postel-Vinay","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100034_bib11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ctrv.2016.05.004","article-title":"Can the response to a platinum-based therapy be predicted by the DNA repair status in non-small cell lung cancer?","volume":"48","author":"Macerelli","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2020.100034_bib12","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa1214271","article-title":"ERCC1 isoform expression and DNA repair in non-small-cell lung cancer","volume":"368","author":"Friboulet","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2020.100034_bib13","doi-asserted-by":"crossref","first-page":"3298","DOI":"10.4161\/cc.26309","article-title":"ERCC1 function in nuclear excision and interstrand crosslink repair pathways is mediated exclusively by the ERCC1-202 isoform","volume":"12","author":"Friboulet","year":"2013","journal-title":"Cell Cycle"},{"key":"10.1016\/j.esmoop.2020.100034_bib14","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ctrv.2016.01.003","article-title":"Cisplatin in the modern era: the backbone of first-line chemotherapy for non-small cell lung cancer","volume":"44","author":"Fennell","year":"2016","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.esmoop.2020.100034_bib15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.lungcan.2007.07.012","volume":"59","author":"Rajeswaran","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib16","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1186\/1741-7015-10-87","article-title":"The failure of protein cancer biomarkers to reach the clinic: why, and what can be done to address the problem?","volume":"10","author":"Diamandis","year":"2012","journal-title":"BMC Med"},{"key":"10.1016\/j.esmoop.2020.100034_bib17","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","article-title":"Cisplatin: mode of cytotoxic action and molecular basis of resistance","volume":"22","author":"Siddik","year":"2003","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2020.100034_bib18","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.esmoop.2020.100034_bib19","doi-asserted-by":"crossref","first-page":"djx059","DOI":"10.1093\/jnci\/djx059","article-title":"Drugging the cancers addicted to DNA repair","volume":"109","author":"Nickoloff","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2020.100034_bib20","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1093\/annonc\/mdw321","article-title":"Predictors of chemotherapy efficacy in non-small-cell lung cancer: a challenging landscape","volume":"27","author":"Olaussen","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2020.100034_bib21","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12943-018-0789-x","article-title":"KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target","volume":"17","author":"Roman","year":"2018","journal-title":"Mol Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11864-018-0557-6","article-title":"Management of KRAS-mutant non-small cell lung cancer in the era of precision medicine","volume":"19","author":"Aredo","year":"2018","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.esmoop.2020.100034_bib23","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1200\/JCO.2008.18.8631","article-title":"Different impact of excision repair cross-complementation group 1 on survival in male and female patients with inoperable non-small-cell lung cancer treated with carboplatin and gemcitabine","volume":"27","author":"Holm","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.esmoop.2020.100034_bib24","doi-asserted-by":"crossref","first-page":"e25164","DOI":"10.1371\/journal.pone.0025164","article-title":"Excision repair cross-complementation group 1 (ERCC1) status and lung cancer outcomes: a meta-analysis of published studies and recommendations","volume":"6","author":"Hubner","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.esmoop.2020.100034_bib25","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1002\/cncr.23693","article-title":"ERCC1 expression as a prognostic marker in N2(+) nonsmall-cell lung cancer patients treated with platinum-based neoadjuvant concurrent chemoradiotherapy","volume":"113","author":"Hwang","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib26","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cllc.2011.04.005","article-title":"Prognostic role of ERCC1 in advanced non-small-cell lung cancer: a systematic review and meta-analysis","volume":"12","author":"Roth","year":"2011","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.lungcan.2011.08.016","article-title":"RT-PCR versus immunohistochemistry for correlation and quantification of ERCC1, BRCA1, TUBB3 and RRM1 in NSCLC","volume":"75","author":"Vilmar","year":"2012","journal-title":"Lung Cancer"},{"key":"10.1016\/j.esmoop.2020.100034_bib28","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.3390\/cancers12092398","article-title":"Impact of ERCC1, XPF and DNA polymerase beta expression on platinum response in patient-derived ovarian cancer xenografts","volume":"12","author":"Guffanti","year":"2020","journal-title":"Cancers (Basel)"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920328994?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702920328994?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:46Z","timestamp":1761855886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702920328994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S2059702920328994"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100034","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Single-arm, open label prospective trial to assess prediction of the role of\u00a0ERCC1\/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2020.100034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier Limited on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100034"}}